Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Sanofi en­lists Ada­gene and its 'mask­ing' tech to de­vel­op new I/O drugs, in a deal po­ten­tial­ly worth $2.5B

Sanofi is putting to­geth­er a new, multi­bil­lion dol­lar deal aim­ing to leap in­to the next gen­er­a­tion of im­muno-on­col­o­gy.

The French phar­ma signed a col­lab­o­ra­tion with Ada­gene on Tues­day to ad­vance two pre­clin­i­cal I/O can­di­dates, and an op­tion to de­vel­op two more. Sanofi is pony­ing up $17.5 mil­lion up­front and promis­ing up to $2.5 bil­lion in po­ten­tial mile­stones.

The deal is slight­ly un­ortho­dox rel­a­tive to how these deals usu­al­ly shake out, as both of the ini­tial pro­grams come from Sanofi’s de­vel­op­ment pipeline — not Ada­gene’s. But the com­pa­nies are aim­ing to link those com­pounds to what Ada­gene calls a “mask­ing” tech­nol­o­gy that can bet­ter se­lec­tive­ly tar­get tu­mor mi­croen­vi­ron­ments than cur­rent ap­proach­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.